Ovid Therapeutics Inc., of New York, priced underwritten public offerings of 12.5 million shares of its common stock and 2,500 shares of its nonvoting series A convertible preferred stock. The public offering price of each share of common stock is $2 and the public offering price of each share of series A stock is $2,000.